Clinical trial of mouse nerve growth factor injection combined with alprostadil injection in the treatment of sudden deafness
10.13699/j.cnki.1001-6821.2018.03.012
- VernacularTitle:鼠神经生长因子注射剂联合前列地尔注射液治疗突发性耳聋的临床研究
- Author:
Hai-Zhu MA
1
;
Shi-Xun ZHONG
Author Information
1. 重庆市人民医院三院院区耳鼻咽喉科
- Keywords:
mouse nerve growth factor injection;
alprostadil injection;
sudden deafness;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(3):231-233
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of mouse nerve growth factor injection combined with alprostadil injection in the treatment of sudden deafness.Methods A total of 96 patients with sudden deafness were divided into control and treatment groups with 48 cases per group.Control group was treated with alprostadil injection 10 μg per time,qd,intravenous injection.Treatment group was treated with mouse nerve growth factor injection 18 μg per time,qd,intramuscular injection,on the basis of control group.Two groups were treated for 10 d.The clinical efficacy,serum vascular cell adhesion factor 1 (sVCAM-1),vascular endothelial cadherin (VE-cadherin),high mobility group protein-1 (HMGB1) and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 93.75％ (45 cases/48 cases) and 75.00％ (36 cases /48 cases) with significant difference (P ＜ 0.05).After treatment,the main indexes in treatment and control groups were compared:sVCAM-1 were (199.20 ±21.50) and (242.99 ± 21.97) ng · mL-1,VE-cadherin were (2.76 ±0.37) and (3.71 ±0.45) mg · L-1,HMGB1 were (1.78 ±0.25) and (2.55 ±0.31) mg · L-1,the differences were statistically significant (all P ＜ 0.05).The adverse drug reactions in treatment group were injection site pain,which in control group were headache and dizziness.The total incidences of adverse drug reactions in treatment and control groups were 6.25％ and 10.42％ without significant difference (P ＞ 0.05).Conclusion Mouse nerve growth factor combined with alprostadil injection has a definitive clinical efficacy in the treatment of sudden deafness,which can effectively reduce the expression of serum sVCAM-1,VE-cadherin and HMGB1,without increasing the incidence of adverse drug reactions.
